title: The intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats.
abstract: OBJECTIVE
  To explore the Intervention effect of Rosiglitozone in ovarian fibrosis of PCOS rats.
  
  
  METHODS
  60 female SD rats were randomly divided into 3 groups: control group, model group and treatment group. The model and treatment groups were established by subcutaneous injection of DHEA, while the treatment group was given RGZ. The serum hormone values, pathohistology of ovarian structure of rats, ovarian ultrastructure and the expressions of TGF-β(1) and CTGF were detected.
  
  
  RESULTS
  The PCOS model was established successfully. The expression intensity of TGF-β(1) and CTGF in Oocytes of the PCOS groups was 9.545±2.954 and 9.665±2.400, respectively and was significantly higher than that of the control group 6.636±2.264 and 7.036±2.133; after treatment with rosiglitazone, the expression was significantly decreased 6.980±2.421 and 6.642±2.721 as compared with that of the model group (P<0.05, P<0.001). The values in serum of the PCOS groups were 3.749±2.054 and 0.265±0.129, and 1.914±1.801 and 0.096±0.088 in the control group which had statistically significant difference (P<0.05, P<0.001). After treatment with rosiglitazone, the values were 2.3100±1.825 and 0.112±0.187 and were significantly different with those of the model group (P<0.05, P<0.001).
  
  
  CONCLUSIONS
  TGF-β(1) and CTGF play an important role in the development of ovary fibrosis in PCOS. However, RGZ may postpone the development of fibrosis by decreasing the levels of TGF-β(1) and CTGF.
authors.affiliation: Department of Reproductive Immunology and Endocrinology, Guangdong Family Planning Research Institute, Guangzhou, Guangdong, China. miaozhulinchn@163.com
authors.forename: Zhu Lin
authors.initials: ZL
authors.lastname: Miao
authors.forename: Liang
authors.initials: L
authors.lastname: Guo
authors.forename: Yong Xia
authors.initials: YX
authors.lastname: Wang
authors.forename: Rong
authors.initials: R
authors.lastname: Cui
authors.forename: Ning
authors.initials: N
authors.lastname: Yang
authors.forename: Mi Qiong
authors.initials: MQ
authors.lastname: Huang
authors.forename: Wei Bing
authors.initials: WB
authors.lastname: Qin
authors.forename: Jin
authors.initials: J
authors.lastname: Chen
authors.forename: Hong Mei
authors.initials: HM
authors.lastname: Li
authors.forename: Zi Neng
authors.initials: ZN
authors.lastname: Wang
authors.forename: Xiang Cai
authors.initials: XC
authors.lastname: Wei
mesh_terms: D000818:Animals; D055513:Connective Tissue Growth Factor / Q000097:blood; D005260:Female; D005355:Fibrosis; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D010053:Ovary / Q000378:metabolism / Q000648:ultrastructure*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta / Q000097:blood
chemical_list: C526316:CCN2 protein, rat; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D016212:Transforming Growth Factor beta; D000077154:Rosiglitazone; D055513:Connective Tissue Growth Factor